Orthocell (OCC) AGM 2024 presentation summary

Financial performance and revenue growth

• FY24 revenue reached $6.76 million, a 30.76% increase from FY23, with a CAGR of 93% since FY22.

• Achieved second consecutive quarter of record revenue, reporting $2.03 million in September 2024.

• Remplir revenue grew 127% year-over-year, and Striate+ revenue increased 14% year-over-year.

• Company maintains a strong balance sheet with $32.8 million cash and no debt.

Product portfolio and innovation

• Collagen medical device platform includes Striate+ for bone repair, Remplir for nerve repair, and SmrtGraft for tendon repair.

• Striate+ and Remplir are revenue-generating in multiple jurisdictions; SmrtGraft tendon scaffold set for Australian launch in 2025.

• Proprietary SMRT manufacturing process ensures high-quality, bioactive collagen devices.

Market expansion and regulatory milestones

• Striate+ approved in US, EU/UK, Australia, and Canada; Remplir approved in Australia, New Zealand, and Singapore.

• Remplir US FDA approval expected Q1 CY25, targeting a $1.6 billion US market.

• Regulatory submissions planned for Canada, Thailand, EU/UK, and Brazil for Remplir; Striate+ expansion into Brazil, Singapore, and Colombia.